Who is sponsoring NCT04819126?

NCT04819126 is sponsored by Kırıkkale University.

What drugs are being tested in NCT04819126?

Interventions in NCT04819126: Nintendo Wii Virtual Reality Application.

What condition does NCT04819126 study?

NCT04819126 studies Age-Related Memory Disorders.

Is NCT04819126 still recruiting?

NCT04819126 is currently completed. Last updated 26 March 2021.

Last reviewed 2021-03-26 · How we verify

NCT04819126

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nintendo Wii Virtual Reality Application In Dementia

Completed NA Last updated 26 March 2021

What this trial tests

NA trial testing Nintendo Wii Virtual Reality Application in Age-Related Memory Disorders in 32 participants. Completed in 15 January 2019.

Timeline

15 January 2018

Primary endpoint
6 June 2018

15 January 2019

Quick facts

Lead sponsor	Kırıkkale University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	32
Start date	15 January 2018
Primary completion	6 June 2018
Estimated completion	15 January 2019
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Nintendo Wii Virtual Reality Application

Conditions studied

Age-Related Memory Disorders — all drugs for Age-Related Memory Disorders →

Sponsor

Kırıkkale University

Who can join

Adults 65 to 80, any sex, with Age-Related Memory Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

•This study was planned to investigate the effects of the Nintendo Wii virtual reality application on muscle strength and fall risk in individuals with AD. The aim of the present study is to investigate the effect of the virtual reality application on muscle strength and fall in individuals with Alzheimer' Dementia (AD).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exergaming for dementia and mild cognitive impairment.
Voinescu A, Papaioannou T, Petrini K, Stanton Fraser D. · · 2024 · cited 9× · PMID 39319863 · DOI 10.1002/14651858.cd013853.pub2

Verify or expand the search:

Other Kırıkkale University trials

Trials by the same sponsor.

NCT07323420 — Effects of Different Inspiratory:Expiratory Ratios on Respiratory and Recovery Outcomes During Dental Procedures Under G · recruiting
NCT07504861 — Biomarkers in Apical Periodontitis · not yet recruiting
NCT07451860 — Chronic Total Occlusion and Triglyceride-Glucose Index · not yet recruiting
NCT06921369 — The Effect of Compassionate Care Education on Nurses · NA · not yet recruiting
NCT07338253 — The Effect of the Flipped Learning Model on Spiritual Care Perception and Competence in Nursing Students · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04819126 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kırıkkale University
Last refreshed: 26 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04819126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing